M&A In the wake of Sanofi’s USD 3.7 billion tie-up for US biotech Principia, J&J has moved to bolster its autoimmune portfolio with the acquisition of Momenta Pharmaceuticals for USD 6.5 billion, a further signal of Big Pharma’s prioritisation of rare disease treatments. The all-cash deal sees J&J’s pharmaceutical division…
See our Cookie Privacy Policy Here